Category Archives: Byetta Cancer
Diabetes Drug-Pancreatitis Link Supported in Another Study

Another study has made a connection between Type 2 diabetes drugs known as incretin mimetics and increased rates of developing pancreatitis, a known precursor to pancreatic cancer. Incretin mimetics, are GLP-1-based diabetes therapies and include Byetta and Bydureon (exenatide); Victoza … Continue reading
Former Pacific Grove Mayor’s Husband Sues Over Wife’s Pancreatic Cancer, Byetta Blamed

The husband of former Pacific Grove, Washington Mayor, Sandy Koffman just filed a wrongful death civil lawsuit against two drug companies following his wife’s death from pancreatic cancer last year. His wife had been taking Type 2 diabetes drug, Byetta. … Continue reading
Gum Disease Tied to Increased Diabetes Risk, May Lead to Increased Risks Tied to Some Type 2 Diabetes Drugs

The links between dental disease and other diseases have been growing, for instance dental disease has been tied to increased risks for developing diabetes and heart disease; pregnancy complications; and, potentially, dementia. Type 2 diabetes is typically treated with any … Continue reading
Despite Increasing Injury Reports, Mounting Lawsuits, and Growing Data, FDA, EMA Will Not Confirm Increased Pancreatic Side Effects with Incretin Drugs

The U.S. Food and Drug Administration (FDA) agrees with the European Medicines Agency (EMA) that prevailing data concerning Type 2 diabetes medications in the class known as glucagonlike peptide-1 (GLP-1)-based diabetes therapies, do not confirm increased pancreatic side effect risks, … Continue reading
Many Popular Medications Contain Cancer-Causing Compounds, May Increase Cancer Risks

Cancer is devastating, killing about 600,000 people every year. Cancer is, in fact, the second-leading cause of death in the United States. Yet, despite consumers’ proactive measures to avoid cancer-causing products, some pharmaceuticals might contain carcinogens, ameliorating the best consumer … Continue reading
Type 2 Diabetes Medication Risks Examined in Journal Review

Incretin mimetics, a class of Type 2 diabetes drugs, are sparking debate and renewing concerns about health risks, especially to the pancreas. In fact, a piece published in the journal BMJ, states that the drugs, which include Byetta and Januvia, … Continue reading
Some Popular Diabetes Medications May Require Additional Review Over Potential Links to Pancreatic Cancer

Type 2 diabetes medications in the class known as incretin mimetics, such as Januvia and Byetta, are under increased scrutiny over recent studies discussing the drugs’ links to pancreatitis and potential increased risks to pancreatic cancer. The makers of these … Continue reading
Januvia, Byetta, Other Diabetes Drugs Focus of Controversy

Some popular and money making diabetes drugs are at the center of a conflict over disturbing research findings. Although Dr. Peter C. Butler declined to test its then-new diabetes medication, Januvia, he ultimately relented and, in 2008, observed that the … Continue reading
Report: Diabetes Drugs Associated with Elevated Cancer Risks
A number of diabetes medications, including Byetta and Januvia, are being probed by the U.S. Food and Drug Administration (FDA) over links to pancreatic cancer. Diabetes drugs manufactured by Merck & Company Inc., AstraZeneca PLC, and other drug makers are … Continue reading
Following U.S. Study, European Union Investigating Diabetes Drugs
Following news in the United States about a recent study that found that Type 2 diabetes drugs, such as Januvia and Byetta, might place patients at increased risk for pancreatic damage, including pancreatic cell growth that could lead to cancer, … Continue reading